Document Detail


Late presentation of opsoclonus-myoclonus-ataxia syndrome in a child with stage 4S neuroblastoma.
MedLine Citation:
PMID:  15956891     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Opsoclonus-myoclonus-ataxia syndrome (OMA) in children is most commonly associated with occult neuroblastoma (NB). Although children with OMA and NB have decreased mortality, they suffer from increased neurologic morbidity. The pathogenesis of OMA in NB is not well understood, but current research and treatments support an immune-mediated process. The authors describe an unusual presentation of OMA occurring following 6 months of chemotherapy in a child with stage 4S NB who presented with partial Horner syndrome. Histopathologic examination of his primary cervical tumor showed NB maturation, which may have played a role in precipitating OMA syndrome. Further study of unusual cases of OMA in NB may provide better understanding of the syndrome and additional treatment options for these children.
Authors:
Linsey S Mutch; Donna L Johnston
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of pediatric hematology/oncology     Volume:  27     ISSN:  1077-4114     ISO Abbreviation:  J. Pediatr. Hematol. Oncol.     Publication Date:  2005 Jun 
Date Detail:
Created Date:  2005-06-15     Completed Date:  2005-07-27     Revised Date:  2011-10-06    
Medline Journal Info:
Nlm Unique ID:  9505928     Medline TA:  J Pediatr Hematol Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  341-3     Citation Subset:  IM    
Affiliation:
Division of Hematology/Oncology, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario K1H 8L1, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Ataxia / etiology*
Humans
Immunoglobulins, Intravenous / therapeutic use
Infant
Male
Neuroblastoma / diagnosis*,  drug therapy*
Paraneoplastic Syndromes, Nervous System / etiology*
Prednisone / therapeutic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Immunoglobulins, Intravenous; 53-03-2/Prednisone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kikuchi-Fujimoto disease is a rare cause of lymphadenopathy and fever of unknown origin in children:...
Next Document:  Complete evidence regarding major vascular injuries during laparoscopic access.